CN109563103B - 用于治疗或预防与其相关的病症的β-3肾上腺素能受体的调节剂 - Google Patents

用于治疗或预防与其相关的病症的β-3肾上腺素能受体的调节剂 Download PDF

Info

Publication number
CN109563103B
CN109563103B CN201780047870.6A CN201780047870A CN109563103B CN 109563103 B CN109563103 B CN 109563103B CN 201780047870 A CN201780047870 A CN 201780047870A CN 109563103 B CN109563103 B CN 109563103B
Authority
CN
China
Prior art keywords
adrenergic receptor
oxa
azaspiro
compound
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780047870.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563103A (zh
Inventor
T-A·德兰
Q-Q·杜
B·厄尔曼
A·C·布莱克本
M·纳古拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN109563103A publication Critical patent/CN109563103A/zh
Application granted granted Critical
Publication of CN109563103B publication Critical patent/CN109563103B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780047870.6A 2016-06-06 2017-06-05 用于治疗或预防与其相关的病症的β-3肾上腺素能受体的调节剂 Active CN109563103B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346293P 2016-06-06 2016-06-06
US62/346,293 2016-06-06
PCT/US2017/035867 WO2017214002A1 (en) 2016-06-06 2017-06-05 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Publications (2)

Publication Number Publication Date
CN109563103A CN109563103A (zh) 2019-04-02
CN109563103B true CN109563103B (zh) 2022-05-27

Family

ID=59067920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780047870.6A Active CN109563103B (zh) 2016-06-06 2017-06-05 用于治疗或预防与其相关的病症的β-3肾上腺素能受体的调节剂

Country Status (29)

Country Link
US (5) US20190284200A1 (enExample)
EP (1) EP3464292B8 (enExample)
JP (3) JP6771246B2 (enExample)
KR (2) KR20190026731A (enExample)
CN (1) CN109563103B (enExample)
AR (1) AR108772A1 (enExample)
AU (2) AU2017278102B2 (enExample)
CA (1) CA3026024C (enExample)
CL (1) CL2018003451A1 (enExample)
CO (1) CO2019000041A2 (enExample)
CR (1) CR20180595A (enExample)
DK (1) DK3464292T3 (enExample)
EA (1) EA201892817A1 (enExample)
EC (1) ECSP19001018A (enExample)
ES (1) ES2929737T3 (enExample)
IL (2) IL289378B (enExample)
MA (2) MA44037B1 (enExample)
MX (2) MX387995B (enExample)
MY (1) MY195982A (enExample)
NI (1) NI201800130A (enExample)
NZ (1) NZ749202A (enExample)
PE (1) PE20190445A1 (enExample)
PH (1) PH12018502550B1 (enExample)
PT (1) PT3464292T (enExample)
SG (1) SG11201810788QA (enExample)
TN (1) TN2018000391A1 (enExample)
TW (2) TWI752963B (enExample)
UA (1) UA125120C2 (enExample)
WO (1) WO2017214002A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
DK3448859T3 (da) 2017-03-20 2019-09-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
ES2953576T3 (es) * 2017-12-06 2023-11-14 Arena Pharm Inc Moduladores del receptor beta-3 adrenérgico útiles para el tratamiento o la prevención de la insuficiencia cardíaca y los trastornos relacionados con la misma
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2022003254A (es) 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
JP2023024954A (ja) * 2021-08-09 2023-02-21 アリーナ ファーマシューティカルズ， インコーポレイテッド ベータ－３アドレナリン作動性受容体に関連する障害の処置または予防に有用なベータ－３アドレナリン作動性受容体のモジュレーター
WO2023026185A1 (en) * 2021-08-26 2023-03-02 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor for the treatment or prevention of renal cystic disease and cardiorenal syndrome
US20240409548A1 (en) * 2021-10-06 2024-12-12 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
EP4479384A1 (en) * 2022-02-14 2024-12-25 Biogen MA Inc. Emopamil-binding protein inhibitors and uses thereof
CN114539103B (zh) * 2022-03-21 2023-04-07 佳木斯黑龙农药有限公司 2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法
CN116178220A (zh) * 2022-12-13 2023-05-30 爱斯特（成都）生物制药股份有限公司 一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363805A (en) * 1980-07-25 1982-12-14 Firma Willmar Schwabe Aminodesoxy-1.4;3.6-dianhydrohexitol nitrates and pharmaceutical composition
WO1999065895A1 (fr) * 1998-06-18 1999-12-23 Sanofi-Synthelabo Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2001043744A1 (fr) * 1999-12-17 2001-06-21 Sanofi-Synthelabo Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2006060122A2 (en) * 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
WO2010058318A1 (en) * 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254595A (en) 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2751646B1 (fr) 1996-07-23 1999-01-22 Sanofi Sa Phenoxypropanolamine a action antagoniste beta3-adrenergique
AU7738298A (en) 1996-12-19 1998-07-15 Agrevo Uk Limited Chromones useful as fungicides
DE20204129U1 (de) 2002-03-15 2002-07-25 Wella Ag, 64295 Darmstadt Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
US8697674B2 (en) 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
AU2009308702B2 (en) 2008-10-31 2015-05-28 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
AU2009308769B2 (en) 2008-10-31 2015-03-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
EP2563764B1 (en) * 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
JP5795799B2 (ja) * 2010-07-23 2015-10-14 メルク・シャープ・エンド・ドーム・コーポレイション 新規なピロリジン由来ベータ３アドレナリン作動性受容体アゴニスト
JP2012092038A (ja) 2010-10-26 2012-05-17 F Hoffmann La Roche Ag 糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤
DK2882428T3 (en) 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
GB201405359D0 (en) 2014-03-25 2014-05-07 Univ Liverpool Synthetic process
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
ES2953576T3 (es) * 2017-12-06 2023-11-14 Arena Pharm Inc Moduladores del receptor beta-3 adrenérgico útiles para el tratamiento o la prevención de la insuficiencia cardíaca y los trastornos relacionados con la misma

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363805A (en) * 1980-07-25 1982-12-14 Firma Willmar Schwabe Aminodesoxy-1.4;3.6-dianhydrohexitol nitrates and pharmaceutical composition
WO1999065895A1 (fr) * 1998-06-18 1999-12-23 Sanofi-Synthelabo Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2001043744A1 (fr) * 1999-12-17 2001-06-21 Sanofi-Synthelabo Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2006060122A2 (en) * 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
WO2010058318A1 (en) * 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors

Also Published As

Publication number Publication date
US20200270264A1 (en) 2020-08-27
CA3026024C (en) 2024-07-02
CN109563103A (zh) 2019-04-02
KR20190026731A (ko) 2019-03-13
IL289378A (en) 2022-02-01
EP3464292B8 (en) 2022-10-26
ES2929737T3 (es) 2022-12-01
NZ749202A (en) 2022-07-01
ECSP19001018A (es) 2019-02-28
TW202237619A (zh) 2022-10-01
US20190389875A1 (en) 2019-12-26
AU2021206809B2 (en) 2023-01-05
JP2019518079A (ja) 2019-06-27
TN2018000391A1 (en) 2020-06-15
KR20220025128A (ko) 2022-03-03
US10927123B2 (en) 2021-02-23
US20190284200A1 (en) 2019-09-19
AR108772A1 (es) 2018-09-26
TWI784840B (zh) 2022-11-21
JP7449329B2 (ja) 2024-03-13
UA125120C2 (uk) 2022-01-12
MX2021014043A (es) 2022-02-21
AU2021206809A1 (en) 2021-08-12
MA45150A (fr) 2021-05-05
PE20190445A1 (es) 2019-03-29
TWI752963B (zh) 2022-01-21
EP3464292A1 (en) 2019-04-10
US20210340154A1 (en) 2021-11-04
CL2018003451A1 (es) 2019-02-22
NI201800130A (es) 2019-06-13
KR102408272B1 (ko) 2022-06-10
MX2018015124A (es) 2019-09-09
JP2020203945A (ja) 2020-12-24
DK3464292T3 (da) 2022-10-31
CA3026024A1 (en) 2017-12-14
JP7083087B2 (ja) 2022-06-10
IL289378B (en) 2022-09-01
US10662200B2 (en) 2020-05-26
TW201803877A (zh) 2018-02-01
MA44037B1 (fr) 2020-03-31
EP3464292B1 (en) 2022-09-21
IL263148B (en) 2022-02-01
PH12018502550A1 (en) 2019-11-04
US20190292196A1 (en) 2019-09-26
SG11201810788QA (en) 2018-12-28
JP2022089984A (ja) 2022-06-16
CR20180595A (es) 2019-04-09
CO2019000041A2 (es) 2019-04-30
MX387995B (es) 2025-03-19
WO2017214002A1 (en) 2017-12-14
AU2017278102A1 (en) 2019-01-17
PH12018502550B1 (en) 2023-01-27
JP6771246B2 (ja) 2020-10-21
IL263148A (en) 2018-12-31
BR112018075201A2 (pt) 2019-03-19
US10479797B2 (en) 2019-11-19
PT3464292T (pt) 2022-11-15
MY195982A (en) 2023-02-27
US11560386B2 (en) 2023-01-24
MA44037A1 (fr) 2019-05-31
AU2017278102B2 (en) 2021-04-29
EA201892817A1 (ru) 2019-06-28

Similar Documents

Publication Publication Date Title
CN109563103B (zh) 用于治疗或预防与其相关的病症的β-3肾上腺素能受体的调节剂
JP7357617B2 (ja) 心不全およびそれに関連する障害の治療または予防に有用なβ－３アドレナリン受容体のモジュレーター
KR20180022982A (ko) Cot 조정제 및 그의 사용 방법
CN102203093A (zh) 氨基三唑并吡啶和其作为激酶抑制剂的用途
CN105658653A (zh) 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
CN101815713A (zh) 多环化合物
CN111278809A (zh) 二环砜类和亚砜类、以及其使用方法
HK40006318B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK40006318A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
BR112018075201B1 (pt) Compostos moduladores do receptor beta-3 adrenérgico e composição farmacêutica que os compreende, seus usos e método de preparação da referida composição
HK40004811B (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
HK40004811A (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
TW202220978A (zh) 雜環化合物
EA041181B1 (ru) Модулятор бета-3-адренергического рецептора, применяемый для лечения или предотвращения связанных с данным рецептором расстройств

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: T-A.Deland

Inventor after: Q-Q.Du

Inventor after: B. Ullman

Inventor after: A.C. Blackburn

Inventor after: M. Nagora

Inventor before: T-A.Deland

Inventor before: Q-Q.Du

Inventor before: B.Ullman

CB03 Change of inventor or designer information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006318

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant